China Biopharmaceutical Industry Report, 2006-2007
  • Mar/2007
  • Hard Copy
  • USD $299
  • Pages:25
  • Single User License
    (PDF Unprintable)       
  • USD $299
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $598
  • Hard Copy + Single User License
  • USD $499
      

In 2006, under the influences of drug depreciation, publishing commercial bribery and the rise in raw material cost, the growth in manufacturing and sales of China pharmaceutical industry slowed down and so did the benefits. Although the sales revenue of the pharmaceutical industry increased by 19.7% year on year, the profit before tax only increased by 6.2%. Since the second quarter of 2006, the growth rate of drugs used in hospitals (first terminal) decreased dramatically to 6.3%, which was the lowest level in recent 10 years; while the retail terminal (second terminal) remained a steady growth, increased by 16.67% over the same period of 2005.

The sales revenue and total profit growth rate of Bio-pharmaceutical industry are 8.2% and 10.9% higher than the average level of pharmaceutical industry respectively, while the sales expenses growth rate is 6.1% lower averagely than the pharmaceutical industry.

Financial Indexes between Bio-pharmaceutical Industry and Pharmaceutical Industry, Jan-Oct, 2006
 

Since 2005, the growth rate of global pharmaceutical market mainly pulled by North America slowed down to below 10%. Meanwhile, as the multi-national companies began to accelerate the globalization strategy, the Chinese market became the competitive hotspot and the investment featured by the sole proprietorship also increased greatly. Besides, the production & research in patent drugs are gradually localized in Chinese market.

The Chinese government is now taking steps to punish the commercial bribery and to standardize the market rule in the pharmaceutical field, and in addition, the drug price is getting decreased, all of which may temporarily restrict the industrial growth but is helpful to make the pharmaceutical administration much stricter and promote those enterprises superior in innovation of product and technology to enlarge market shares.

Bio-pharmaceuticals mainly engage in prescription drug. The old pharmaceutical products (including bacterin) have become very popular among doctors and patients owing to its higher performance-price ratio, so the sales also kept stable. However, the popularization of the new-born bio-pharmaceuticals in hospitals and disease control centers has to be confronted with the challenges in sales modes and price-making policy from multi-national pharmaceutical giants. So, it is imperative and necessary for sales increase of new prescription drug to catch up with the international academic extension model as soon as possible.

As the investment hotspot of China bio-pharmaceutical industry, the growth of bacterin, especially the bacterin outside plan, is far higher than that of the normal treatable drugs; the R&D of monoclonal antibody drug is quite active because of its strong pertinence and low risks in clinical research.

1. Development Overview of China Bio-pharmaceutical Industry
1.1 Operation Status of China Bio-pharmaceutical Industry in 2006
1.2 Analysis on Key Bio-pharmaceutical Enterprises in China
1.2.1 Beijing Tiantan Biological Products Corporation Limited
1.2.2 Hualan Biological Engineering Inc.
1.2.3 Others

2. Prospect and Opportunities of China Bio-pharmaceutical Industry
2.1 Prospect
2.2 Investment Opportunities
Total Profit Growth Rate of China Bio-pharmaceutical Industry, Jan-Oct 2006
Sales Profit Margin of China Bio-pharmaceutical Industry, Jan-Oct 2006
Monthly Operation Growth Rate of China Bio-pharmaceutical Industry, Jan-Oct 2006
Growth Rate of Financial Indexes of Sub-industries of China Bio-pharmaceutical Industry, Jan-Oct 2006
List of Investment Subjects of China Bio-pharmaceutical Industry, 2007
Leading Products of Biological Institutes under China National Biotec Group
Forecast of Business Integration on Blood Products
Existing Therapeutic Monoclonal Antibody Drugs in China

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统